Scientists look at cost-effectiveness of Erbitux

06/29/2009 | Bloomberg

The $80,000 price tag for Eli Lilly and Co. and Bristol-Myers Squibb's cancer drug Erbitux is too high considering it prolongs patients' survival only about 1.2 months more when combined with other treatments than chemotherapy alone, two U.S. scientists said in a commentary in the Journal of the National Cancer Institute. Bristol-Myers estimated that Erbitux costs about $10,000 a month, a company spokesman said, and the product is not meant for all cancer patients.

View Full Article in:

Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
CarePoint Health Plan
Jersey City, NJ
Regional Director, Southeastern Region - State Affairs
America's Heatlh Insurance Plans (AHIP)
Washington, DC
Assistant General Counsel
Cardinal Health
Columbus, OH
Pharmacy Care Manager
National Association of Chain Drug Stores
Arlington, VA
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC